PC-PLD1 Inhibitors
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
VU0155069 | 1130067-06-9 | sc-224371 sc-224371A sc-224371B sc-224371C | 1 mg 5 mg 10 mg 25 mg | $70.00 $173.00 $291.00 $510.00 | 7 | |
VU0155069 functions as a selective modulator of phospholipase D1, characterized by its ability to disrupt lipid organization within cellular membranes. This compound engages in specific hydrophobic interactions that can lead to altered membrane fluidity and permeability. Its unique structure facilitates the formation of transient lipid domains, influencing enzymatic activity and substrate accessibility. Furthermore, VU0155069 can impact the localization of signaling molecules, thereby modulating intracellular communication. | ||||||
CAY10594 | 1130067-34-3 | sc-223874 sc-223874A | 1 mg 5 mg | $82.00 $266.00 | 8 | |
CAY10594 acts as a potent inhibitor of phospholipase D1, exhibiting a unique ability to alter lipid metabolism through specific interactions with membrane phospholipids. This compound enhances the stability of lipid bilayers, leading to modified enzymatic pathways and substrate interactions. Its distinctive chemical structure promotes the formation of lipid microdomains, which can influence cellular signaling cascades and affect the dynamics of membrane-associated proteins. | ||||||
Halopemide | 59831-65-1 | sc-221704 sc-221704A | 5 mg 25 mg | $123.00 $371.00 | ||
Halopemide functions as a selective inhibitor of phospholipase D1, demonstrating a remarkable capacity to modulate lipid signaling pathways. Its unique molecular architecture facilitates specific binding interactions with phospholipid substrates, resulting in altered reaction kinetics. This compound can disrupt lipid raft formation, thereby influencing membrane fluidity and the localization of signaling molecules. Additionally, Halopemide's reactivity as an acid halide allows for diverse chemical transformations, enhancing its role in lipid metabolism regulation. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine acts as an indirect inhibitor of PC-PLD1 by influencing serotonin signaling. As a selective serotonin reuptake inhibitor (SSRI), fluoxetine modulates serotonin levels, which, in turn, affects downstream signaling events connected to PC-PLD1 pathways. This indirect inhibition provides a regulatory mechanism through the modulation of neurotransmitter signaling, influencing cellular processes governed by PC-PLD1. | ||||||
FIPI | 939055-18-2 | sc-294594 sc-294594A sc-294594B sc-294594C | 1 mg 5 mg 10 mg 25 mg | $60.00 $171.00 $306.00 $692.00 | 2 | |
FIPI serves as a potent inhibitor of phospholipase D1, characterized by its ability to selectively engage with lipid substrates through unique hydrophobic interactions. This compound alters enzymatic activity by stabilizing specific conformations of the enzyme, leading to modified reaction kinetics. Its behavior as an acid halide enables it to participate in various acylation reactions, influencing lipid dynamics and cellular signaling pathways. FIPI's distinct molecular properties contribute to its role in lipid homeostasis. | ||||||
FIPI hydrochloride | 1781834-93-2 | sc-300694 | 5 mg | $258.00 | 1 | |
FIPI hydrochloride is a selective inhibitor of phospholipase D1, distinguished by its unique ability to form stable complexes with the enzyme's active site. This interaction modulates the enzyme's conformation, resulting in altered catalytic efficiency. As an acid halide, FIPI hydrochloride engages in acylation processes, impacting lipid metabolism and cellular signaling. Its specific molecular characteristics facilitate targeted interactions, influencing lipid-related pathways and cellular functions. | ||||||
VU0359595 | 1246303-14-9 | sc-475843 | 5 mg | $190.00 | 1 | |
VU0359595 is a potent inhibitor of phospholipase D1, characterized by its ability to disrupt enzyme-substrate interactions through specific binding at the active site. This compound alters the enzyme's structural dynamics, leading to a decrease in catalytic activity. As an acid halide, VU0359595 participates in acylation reactions, influencing lipid signaling pathways and cellular processes. Its unique molecular properties enable precise modulation of lipid metabolism, affecting various cellular functions. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
D609 serves as a direct inhibitor of PC-PLD1. By interacting with the phospholipase D domain, D609 directly targets and inhibits the enzymatic activity of PC-PLD1, disrupting the hydrolysis of phosphatidylcholine. This direct inhibition interferes with the normal cellular processes regulated by PC-PLD1, impacting membrane dynamics and signaling pathways associated with this enzyme. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin acts as an indirect inhibitor of PC-PLD1 through its influence on the PI3K/AKT/mTOR pathway. By inhibiting the PI3K/AKT/mTOR pathway, cisplatin indirectly impacts downstream events connected to PC-PLD1 pathways. This indirect inhibition provides a regulatory mechanism through the modulation of a shared signaling pathway, influencing cellular processes governed by both PI3K/AKT/mTOR and PC-PLD1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as an indirect inhibitor of PC-PLD1 by targeting the PI3K/AKT pathway. Through its inhibition of PI3K, wortmannin indirectly influences downstream signaling events connected to PC-PLD1 pathways. This indirect inhibition provides a regulatory mechanism through the modulation of a shared signaling pathway, influencing cellular processes governed by both PI3K/AKT and PC-PLD1. | ||||||